Alkermes plc. Quantifying Misstatement in Current Year Financial Statements, Amount
Alkermes plc. (ALKS) reported Quantifying Misstatement in Current Year Financial Statements, Amount of $1.00 million for the 3-month period ending 2013-06-30, per its 10-KT filed 2014-02-27.
Discontinued › Notes
us-gaap:QuantifyingMisstatementInCurrentYearFinancialStatementsAmount · last filed 2014-02-27
- Alkermes plc. quantifying misstatement in current year financial statements, amount for the quarter ending 2013-06-30 was $1.00M.
| Period end | Quantifying Misstatement in Current Year Financial Statements, Amount 3 month |
|---|---|
| 2013-06-30 | $1.00M 10-KT · filed 2014-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |